COBIMETINIB FUMARATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for cobimetinib fumarate and what is the scope of freedom to operate?
Cobimetinib fumarate
is the generic ingredient in one branded drug marketed by Genentech Inc and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.Cobimetinib fumarate has one hundred and seventy-seven patent family members in forty-three countries.
One supplier is listed for this compound.
Summary for COBIMETINIB FUMARATE
International Patents: | 177 |
US Patents: | 7 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 10 |
Patent Applications: | 1 |
DailyMed Link: | COBIMETINIB FUMARATE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for COBIMETINIB FUMARATE
Generic Entry Date for COBIMETINIB FUMARATE*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for COBIMETINIB FUMARATE
Drug Class | Kinase Inhibitor |
Mechanism of Action | Kinase Inhibitors |
US Patents and Regulatory Information for COBIMETINIB FUMARATE
International Patents for COBIMETINIB FUMARATE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Mexico | 2022015606 | COMPRIMIDOS DE LIBERACION INMEDIATA QUE CONTIENEN UN FARMACO Y PROCESOS PARA FORMAR LOS COMPRIMIDOS. (IMMEDIATE-RELEASE TABLETS CONTAINING A DRUG AND PROCESSES FOR FORMING THE TABLETS.) | ⤷ Try a Trial |
South Africa | 201708760 | CRYSTALLINE FUMARATE SALT OF (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)PHENYL] [3-HYDROXY-3-(PIPERIDIN-2-YL) AZETIDIN-1-YL]-METHANONE | ⤷ Try a Trial |
Japan | 2021138716 | 薬物を含有する即放性錠剤及び錠剤の形成プロセス (IMMEDIATE RELEASE TABLET CONTAINING DRUG AND PROCESS FOR FORMING TABLET) | ⤷ Try a Trial |
Chile | 2017003475 | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona | ⤷ Try a Trial |
Colombia | 7180225 | Tratamientos de combinación para melanoma que comprenden la administración de cobimetinib y vemurafenib | ⤷ Try a Trial |
Lithuania | PA2016016 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for COBIMETINIB FUMARATE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1934174 | CR 2016 00021 | Denmark | ⤷ Try a Trial | PRODUCT NAME: COBIMETINIB OG FARMACEUTISK ACCEPTABLE SALTE OG SOLVATER DERAF, SAERLIGT COBIMETINIB HEMIFUMARAT; REG. NO/DATE: EU/1/15/1048 20151124 |
1934174 | PA2016016 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: KOBIMETINIBAS; REGISTRATION NO/DATE: EU/1/15/1048 20151120 |
1934174 | 2016/022 | Ireland | ⤷ Try a Trial | PRODUCT NAME: COBIMETINIB, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS AND SOLVATES, IN PARTICULAR COBIMETINIB HEMIFUMARATE.; REGISTRATION NO/DATE: EU/1/15/1048/001 20151120 |
1934174 | 650 | Finland | ⤷ Try a Trial | |
1934174 | C20160012 00193 | Estonia | ⤷ Try a Trial | PRODUCT NAME: KOBIMETINIIB;REG NO/DATE: EU/1/15/1048 24.11.2015 |
1934174 | 364 5005-2016 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: KOBIMETINIB VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/15/1048/001 20151124 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.